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Background: Although the HPV vaccine is available for a fee in Nigeria it is not yet in the 
National Programme on Immunization (NPI) which is free. Health care workers can play an 
important role in improving uptake of the vaccine and in advocating for its inclusion in the 
NPI. However, this role may be limited by lack of knowledge. This study assessed the effect 
of training on health care workers’ knowledge of HPV, its relationship with cervical cancer 
and the role of HPV vaccine in prevention.   
Methods: This quasi-experimental study examined the responses to pre and post test 
evaluation of the knowledge and practice of health care workers from Benin City with regards 
to HPV, cervical cancer and HPV vaccines at a workshop organized to create awareness on 
the subject matter. 
Results: Of the 53 health care workers at the training, 46 (85%) knew that HPV was the 
causative agent of cervical cancer while only 13 (28.9%) and 15 (32.6%) knew that it was 
associated with oral and vaginal cancer, respectively.  Majority of participants had heard 
about the HPV vaccine but only 15 (30.6%) had encouraged its use and 7 (14.3%) had 
prescribed it. Post test result showed marked improvement in most areas evaluated. 
Conclusion: The less than satisfactory knowledge of health care workers about HPV and its 
relationship with anogenital cancers was markedly improved by training. Training of health 
care workers should be done to address the dearth of knowledge prior to the deployment of 
the vaccine nationally. 
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INTRODUCTION 
Human Papilloma Virus (HPV) infection is 
one of the commonest sexually transmitted 
infections globally.1 At least 50% of sexually 
active females will acquire the infection in 
their life time.2 While most of the infections are 
asymptomatic, transient and clear 
spontaneously, persistent infection with 
certain genotypes have been associated with 
lesions.1 HPV has over 100 genotypes which 
are classified as high risk and low risk based 
on their propensity to cause malignant 
lesions.1,2 About 70% of cervical cancer is 
caused by genotypes 16 and 18 which are 
considered high risk while types 6 and 11 
which are associated with genital warts are 
considered low risk.1, 3 Other cancers that have 
been associated with HPV include oral, penile, 
anal, vulval and vaginal cancers.3 Cervical 
cancer is the commonest gynaecological 
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cancer worldwide affecting 500,000 women 
annually, most of whom are from low income 
countries.4 The age standardized rate of 
cervical cancer in Nigeria is reported as 34.5 
per 100,000 women suggesting high burden of 
both the HPV and cervical cancer.5 Known risk 
factors for acquisition of the HPV and 
development of cervical cancer have been 
recognized and these include early sexual 
debut, multiple sexual partners, smoking, 
history of sexually transmitted diseases, 
multiparity, immunodeficiency and long term 
use of oral contraceptives.6 
Several strategies have been deployed to 
prevent cervical cancer. These include health 
education, regular screening for cervical 
cancer using the Papaniculao (PAP) smear and 
more recently primary prevention using the 
HPV vaccine. There are three types of the HPV 
vaccine – the bivalent (against genotypes 16 
and 18), the quadrivalent (against genotypes 6, 
11, 16 and 18) and the nonavalent (against 9 
genotypes).7 The HPV vaccine has not yet been 
deployed in the National Programme on 
Immunization (NPI) in Nigeria but it is 
available for a fee. Health care professionals 
have been identified as important in driving 
the uptake of health interventions.8 Thus their 
knowledge and attitudinal disposition to the 
HPV vaccine will be important in creating 
demand for the vaccine. They are also in a 
good position to advocate for the vaccine to be 
deployed in the NPI. Several studies have 
evaluated health care workers knowledge and 
attitude towards HPV in Nigeria.1, 4, 9 Many of 
these studies tend to target female health care 
workers both as potential recipients of the 
vaccine and also as administrators of the 
vaccine; majority of administrators are nurses 
who are mostly female.1, 9 Some of these 
studies highlighted poor knowledge about 
HPV vaccines.1, 4, 9  
The Institute of Child Health, University of 
Benin which regularly disseminates health 
information, decided to close the information 
gap by organizing a workshop for health care 
workers on cervical cancer and HPV vaccine. 
The pretest and post-test evaluations of the 
workshop participants are the subject of this 
study. The aim of this study was to assess the 
effect of training on the knowledge of the 
health care workers about HPV infection, 
cervical cancer and its prevention. 
METHODOLOGY 
The Institute of Child Health in collaboration 
with the Department of Child Health, 
University of Benin, Benin City, organized a 
workshop on HPV vaccines and cervical 
cancer for health care workers in Benin City in 
November 2015. Participants were drawn 
from the four major hospitals (University of 
Benin Teaching Hospital, Central Hospital, 
Faith Mediplex and St Philomena’s Hospital) 
in Benin City in addition to other private 
health facilities following receipt of letters of 
invitation to attend the workshop. Intended 
participants were doctors, nurses, pharmacists 
and laboratory scientists. All those who 
attended the seminar are the subject of this 
quasi-experimental study (one group pretest-
post-test design). Benin City which is largely 
urban is the capital of Edo State and has a 
population of 1,085,676. There are 318 
registered hospitals/clinics in Benin City. A 
set of pretest questions were administered 
before the workshop took place and the same 
set of questions were administered at the end 
of the workshop. Lectures were given over a 
two hour period which covered the subject 
areas of the HPV, its genotypes, prevalence, 
risk factors, cervical cancer and its prevention 
including HPV vaccination.  
The pretest questions also sought 
demographic information such as designation, 
age and number of years since graduation. 
Verbal consent was obtained from the 
participants. The questionnaires had no 
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identifiers and the pre- and post-test 
questionnaires were not linked for a given 
individual.  Responses were coded and 
entered into a Statistical Package for Social 
Sciences (SPSS) version 16 spread sheet. 
Analysis was done using the same software. 
The distribution of the respondents according 
to their responses to knowledge, attitude and 
practice questions were presented as simple 
proportions. Continuous variables such as age 
were presented as means with standard 
deviations. Comparison of responses between 
pre and post workshop was done using 
Fishers Exact test and Chi Square test as 
appropriate. Level of statistical significance 
was set at p<0.05. Ethical clearance for the 
study was obtained from the Research and 
Ethics Committee of the College of Medical 
Sciences, University of Benin. (REC Exemption 
No: CMS/REC/2017/001) 
RESULTS 
There were 53 respondents who answered the 
pretest questions 31 (58.5%) doctors, 21 
(39.6%) nurses and 1 (1.9%) laboratory 
scientist) while 42 answered the post test 
questions 20 (47.6%) doctors, 21 (50.0%) nurses 
and 1 (2.4%) laboratory scientist). Some 11 
(20.8%) did not stay till the end of the 
workshop/did not respond to the post test 
questions. Among the pretest respondents, 
there were 16 (30.2%) males and 37 (69.8%) 
females while there were 10 (23.8%) males and 
32 (76.2%) females among the post-test 
respondents. The age distribution of the 
respondents is shown in Table 1. The mean 
ages of the respondents in the pre- and post-
tests were 39.8 ± 9.4 and 40.3 ± 9.7 years, 
respectively. 
Knowledge about cervical cancer 
Majority of respondents 50 (94.4%) knew that 
multiple sexual partners is a risk factor for 
cervical cancer. Knowledge about other risk 
factors is as shown in Table 2. With regards to 
symptoms of cervical cancer, the most 
recognized symptom was post coital bleeding. 
Following training all respondents correctly 
identified risk factors and symptoms of 
cervical cancer. The difference between pre 
and post training responses in correctly 
identifying risk factors and symptoms was 
statistically significant (p<0.0001) except for 
multiple sexual partners in which the 
difference was not significant. In terms of 
prevention, 32 (60.4%) of respondents 
recognized that primary prevention can be 
achieved with the HPV vaccine but 11 (20.8%) 
erroneously believed that PAP smears were 
not necessary if an individual had received the 
HPV vaccine while only 16 (30.2%) affirmed 
that Pap smears were necessary even after 
receipt of HPV vaccines. Some respondents 34 
(64.1%) correctly identified that Pap smear 
should be done 3 yearly for sexually active 
females. All respondents at the end of the 
workshop recognized HPV vaccine as a 
primary prevention tool and that Pap smear 
should be done three yearly. The 
improvement in the post workshop responses 
was statistically significant (p<0.0001). 
Knowledge about HPV 
Forty-six (86.8%) respondents knew that HPV 
was responsible for cervical cancer while 13 
(24.5%) and 15 (28.3%) knew that it was also 
implicated in oral and vaginal cancers, 
respectively. These proportions significantly 
increased following the training (p<0.0001). 
With regards to cancer causing HPV 
genotypes, 32 (60.4%) and 15 (28.3%) of 
respondents knew that HPV 16 and 18 as well 
as 31 and 45 were causative of cervical cancer.  
Seven (13.2%) of respondents erroneously 
believed that HPV 6 and 11 were also causative 
of cervical cancer and this proportion 
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Table 1: Sociodemographic characteristics of  
participants 
 Socio-demographic          Frequency      Percent 
characteristic                         (n=53)                                                       
Gender 
Male                                        37                   69.8 
Female                                    16                   30.2 
 
Age group (years) 
≤29                                             7                   13.2 
30-39                                        13                  24.5 
40-49                                        17                  32.1            
≥50                                           10                  18.9 





     Consultants                          7                  22.6 
     Residents                            17                  54.8 
     House officers                     5                   16.1 
     Medical Officers                 2                     3.8 
Nurses 
    NO1 & NO11                       4                   19.0          
    SNO & PNO                         8                   38.1 
   ACNO & CNO                      7                   33.3 
   Not indicated                        2                     9.5 
Laboratory Scientist              1                      4.8           
 
Numbers years since  
graduation 
≤9                                               16                30.2 
10-19                                          16                30.2 
20-29                                           7                 13.2 
≥30                                              6                 11.3                                                 
Not indicated                            8                 15.1 
 
Knowledge about HPV Vaccine  
Majority of the respondents 46 (86.8%) had 
heard about the HPV vaccine Prior to the 
training less than 30% of respondents knew of 
the different types of HPV vaccines but this 
increased to 100% (42) at the end of the 
training (p<0.0001). With regards to 
indications for the HPV vaccine, 41 (77.4%) 
agreed that it should be administered to young 
girls prior to sexual debut whereas 27 (50.9%) 
thought it should be given to all sexually 
active females. Only 27 (50.9%) of respondents 
knew that 3 doses of the vaccine are required 
while 35 (66.0%) knew that the 
recommendation is that the HPV should be 
administered from the age of 9 years. 
Following the workshop, all respondents 42 
(100.0%) agreed that the vaccine should be 
given to young girls prior to sexual debut. 
They also knew the correct recommendation of 
3 doses of the vaccine and that it should be 
administered to girls from the age of 9 years. 
This increase in knowledge was statistically 
significant (p<0.0001). However, 21 (50.0%) 
still felt that it should be given to all sexually 
active females and this was not statistically 
significantly different from the pre workshop 
proportion (p=1.000).  
Correct identification of the different side 
effects of the vaccine is shown in Table 3. More 
participants 30 (56.6%) recognized pain, 
swelling and redness at injection site as side 
effects of the HPV vaccine compared to other 
symptoms (fever, headache, dizziness, nausea, 
vomiting and diarrhoea) although the 
differences were not statistically significant, 
χ2=4.854, p=0.883. Post training, all 
respondents 42 (100.0%) correctly identified 
the side effects of the vaccine. The increase in 
the proportion correctly identifying side 
effects was statistically significant (p<0.0001). 
A significant proportion of respondents did 
not know that the HPV vaccine was protective 
against genital warts 29 (54.7%) and penile 
cancer 40 (75.5%) but at the end of the 
workshop all respondents recognized the 
protective ability of the vaccine against genital 
warts and penile cancer p<0.0001. Majority 40 
(75.5%) of the respondents did not know that 
the HPV vaccine was expensive but this 
awareness increased to 42 (100%) at the end of 
the workshop (p<0.001). 
DISCUSSION 
This study shows that prior to the seminar, 
there was a significant knowledge gap that 
could negatively impact the ability of the 
health care workers to effectively advocate for 
the use of the HPV vaccine. Although many 
respondents were knowledgeable about  
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Table 2: Knowledge of participants about cervical cancer and other HPV associated cancers 
Knowledge Domains                                       Respondents who gave a yes response    
                                                                                       Pretest               Post test            
                                                                                       n=53                     n=42 
                                                                                       n (%)                     n (%)                          p value 
Common features of cervical cancer                                                                                                                               
Post coital bleeding                                                    50 (94.3)           42 (100.0)                        0.2500                                                                                                                   
Irregular vaginal bleeding                                        39 (73.6)           42 (100.0)                      <0.0002                            
Painful coitus                                                              31 (58.5)           42( 100.0)                      <0.0001                                            
headache                                                                       4 (7.6)                0 (0.0)                            0.1271 
Risk factors for cervical cancer                                                                                                                 
Multiple sexual partners                                           51 (94.4)           42 (100.0)                        0.5015                                                                                                                                   
Smoking                                                                       24 (45.3)           42 (100.0)                     <0.0001                                                                                              
Long term use of oral contraceptives                      16 (30.2)           42 (100.0)                     <0.0001                                            
Not breastfeeding                                                       10 (18.9)           42 (100.0)                     <0.0001       
Cause of Cervical cancer                                           
HPV 16 and 18                                                             32 (60.4)           42 (100.0)                    <0.0001                                       
HPV 6 and 11                                                                7 (13.2)            21 ( 50.0)                     <0.0001                                                                                                           
HPV 31 and 45                                                             15 (28.3)           42 (100.0)                    <0.0001 
HPV-associated cancers                                                                                                                                                      
Oral cancer                                                                   13 (24.5)           41 (97.6)                      <0.0001                                                                                                                                                                  
Vaginal cancer                                                             15 (28.3)           42 (100.0)                    <0.0001                                          
Cervical cancer                                                            46 (86.8)           42 (100.0)                       0.0164                             
Condyloma acuminata                                               15 (28.3)           37 (88.1)                      <0.0001 
 
Table 3:  Knowledge of participants about HPV Vaccine
Knowledge domains                                                           Respondents who gave a yes response      
                                                                                                          Pretest                  Post test 
                                                                                                            n=53                      n=42 
                                                                                                            n (%)                     n (%)              p-value 
 Use of HPV Vaccine                                                                                                                                                                  
I have heard about it                                                                     46 (86.8)               42 (100.0)            0.0164                                                                                   
I have encouraged my patients to receive it                              15 (28.3)                                                                                                                  
I have prescribed if for my patients                                              7 (13.2)         
Types of HPV Vaccines                                                                                                                                             
Bivalent                                                                                           14 (26.4)                 42 (100.0)         <0.0001                                                                                                                                              
Tetravalent                                                                                     11  (20.8)                42 (100.0)         <0.0001                                                  
Nonavalent                                                                                      2 (  3.8)                 42 (100.0)         <0.0001 
HPV vaccine administration                                                                                                                                        
It is given as a single shot                                                             6 (11.3)                   0 (0.0)              <0.0325                                                                                    
It is given in 3 doses                                                                     27 (50.9)                42 (100.0)          <0.0001                                 
It is best given to young girls prior to sexual debut                41 (77.4)                42 (100.0)          <0.0009                                                          
It is best given to all sexually active females                            27 (50.9)                21 (50.0)              1.0000                             
It is given from the age of 9 years                                               35 (66.0)                42 (100.0)            0.0001                                                                                                                                                                                                  
Concerning Pap Smear                                                                                                                                                                                                    
Pap smear screening is not necessary after receipt of HPV    11 (20.8)                21 (50.0)              0.0042                                                                                                                             
vaccine                                                                                             
Pap smear should be done 3 yearly as from age 20 for           34 (64.1)                42 (100.0)          <0.0001                                                                              
sexually active females                                                                                           
Uses of HPV vaccine                                                                                                                                                  
HPV vaccine is a primary prevention tool                               32 (60.4)                42 (100.0)          <0.0001 
Protects against genital warts                                                      4 (45.3)                 42 (100.0)          <0.0001                                                                                                            
Protects against penile cancer                                                    13 (24.5)                 42 (100.0)          <0.0001              
Side effects of HPV vaccine                                                                                                                                     
Pain, swelling and redness at injection site                              30 (56.6)                42 (100.0)          <0.0001                                                                                            
Mild fever, headache, dizziness                                                 25 (47.2)                42 (100.0)          <0.0001                                                   
Nausea, vomiting, diarrhoea                                                      19 (35.9)                42 (100.0)          <0.0001                                                                                                            
Runny nose                                                                                     6 (11.3)                     0  ( 0.0)             0.0325 
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cervical cancer in terms of its general cause 
and symptoms, a significant proportion were 
not knowledgeable about risk factors beyond 
the role of multiple sexual partners. The 
finding of poor knowledge of risk factors has 
been identified in previous works both in 
Nigeria and elsewhere.10-12 One of the 
fundamental requirements for the prevention 
of a disease is the knowledge about the various 
risk factors for the disease. 
Beyond knowing that genotypes 16 and 18 
were causative of cervical cancer, the 
knowledge about the roles of other HPV 
genotypes was low. Most previous studies on 
knowledge in Nigeria did not evaluate 
knowledge about the HPV genotypes.1, 4, 9 It is 
important to know about the various cancer 
causing HPV genotypes as this information is 
needed to understand and explain the 
need/indications and scope of the different 
types of HPV vaccines. The respondents also 
exhibited poor knowledge about other 
diseases associated with the HPV. Information 
about the spectrum of diseases associated with 
the HPV is important in explaining the 
advantages of the HPV vaccine in general and 
the advantages of different types of HPV 
vaccines.  A previous Nigerian study that 
assessed knowledge of other HPV associated 
diseases restricted this to warts and penile 
cancer and the knowledge about this was low 
as found in this study.4 
Prevention of cervical cancer involves 
different approaches. HPV vaccine is a 
primary prevention tool and only two-thirds 
of respondents recognized it as such. It is 
generally agreed that HPV vaccine is best 
given to young girls prior to their sexual debut 
and majority of the respondents knew this. 
This is similar to findings in other Nigerian 
studies in which majority of respondents 
favoured administering the vaccine to young 
girls.1, 4 There are some studies which have 
reported resistance to giving the vaccines to 
adolescent girls and the reasons included fear 
of encouraging initiation of sexual activity.1, 8 
About half of the respondents felt the vaccine 
should be given to all sexually active females 
and this proportion did not change 
significantly after the workshop. The problem 
with such an approach is the fact that the 
vaccine would be administered to those who 
may have already acquired the virus and for 
whom the vaccine will not be beneficial. This 
approach may not be cost effective. However, 
infected sexually active females may not have 
acquired the HPV genotypes covered by the 
vaccine. In such instances receipt of the 
vaccine may be beneficial in that it will 
provide protection against the vaccine 
serotypes. 
With regards to the role of Pap smear after 
receipt of the vaccine, about a fifth of 
participants felt that this was not required 
after receipt of the vaccine and this proportion 
increased after the workshop. Such erroneous 
belief could lead to a decline in uptake in Pap 
smear testing when the HPV vaccine becomes 
widely available. It is important that health 
care workers understand the roles of Pap 
smear and HPV vaccine in the prevention of 
cervical cancer.  The HPV vaccine is not 100% 
efficacious and none of the yet available 
vaccines covers all cervical cancer causing 
genotypes.13, 14 Thus receipt of the vaccine is 
not totally protective and the Pap smear will 
continue to be a relevant tool for early 
detection of pre-cancerous lesions. 
Majority of the respondents had heard of the 
HPV vaccines. This is higher than in earlier 
studies carried out in 2008 and 2011 
suggesting an increase in the availability of 
information on the HPV vaccines over time.1, 9 
In this study only about a third of the 
participants had encouraged its use among 
their patients and fewer still had ever 
prescribed it. This is lower than findings in 
Enugu in which almost fifty percent of 
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married respondents with adolescent 
daughters had had them immunized.9 It is 
important that health care workers should 
encourage the use of the HPV vaccine. In 
health care settings, it has been recognized that 
the advice of health care workers with regards 
to HPV vaccine was a significant determinant 
of uptake of the vaccine.8 The dearth of 
knowledge about important aspects of the 
HPV vaccine may have been responsible for 
the observations in the respondents with 
respect to the use of the vaccine. Previous 
studies have shown that health care workers 
are reluctant to prescribe the HPV vaccine 
when they have limited knowledge about its 
efficacy and safety.1, 4 
The workshop met its intended objectives of 
improving knowledge and raising awareness 
of participants about cervical cancer and the 
HPV vaccine as evidenced by the 
improvement in most aspects. This study is 
limited by the small number of participants 
and the fact that the pre and post tests were not 
linked. It is concluded that the knowledge 
about HPV among health care workers is low 
and there should be concerted efforts and 
plans to address the dearth of knowledge prior 
to the deployment of the vaccine. Areas of 
emphasis should include the roles of the 
vaccine and the Pap smear so that deployment 
of the vaccine will not result in a reduction in 
the uptake of Pap smear screening. Pre-service 
training and in-service training are suggested 
strategies for achieving this objective. 
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